莱特莫韦与马立巴韦的药物相互作用管理:临床医生指南
莱特莫韦和马立巴韦分别用于预防和治疗免疫抑制患者的巨细胞病毒感染,患者常多药合用存在药物相互作用风险。两者既是肇事者也是受害者,与免疫抑制剂、抗真菌药及血液肿瘤药物等合用时需调整剂量或密切监测,部分情形需评估三向相互作用。本文基于现有药物相互作用研究数据,为临床医生提供管理指导,并外推至尚未研究但常用的合并用药。
要点
- 莱特莫韦是CYP3A、CYP2C8和OATP1B1/3的中度抑制剂,CYP2C19的中度诱导剂,也是UGT1A1/3、BCRP、P-gp和OATP1B1/3的底物。
- 马立巴韦是CYP2C9的中度抑制剂和CYP3A的底物。
- 与免疫抑制剂、抗真菌药和血液肿瘤药物等合用时可能需调整剂量或密切监测,部分情形需评估三向相互作用。
核心结论
- 莱特莫韦和马立巴韦与多类治疗药物存在具有临床后果的药物相互作用,需调整剂量或密切监测。
- 部分药物组合需评估三向药物相互作用。
研究设计与样本
- 本文为综述,基于现有药物相互作用研究数据,并为尚未研究但常用合并用药提供外推指导。
主要发现
- 莱特莫韦是CYP3A、CYP2C8和OATP1B1/3的中度抑制剂,是CYP2C19的中度诱导剂。
- 莱特莫韦是UGT1A1/3、BCRP、P-gp和OATP1B1/3的底物。
- 马立巴韦是CYP2C9的中度抑制剂,是CYP3A的底物。
- 与免疫抑制剂、抗真菌药和血液肿瘤药物等合用时可能需剂量调整或密切监测。
临床怎么用
- 临床医生应参考本文指导管理莱特莫韦或马立巴韦与其他药物的相互作用。
- 对尚未研究但常用的合并用药,可基于转运体和代谢酶特征外推管理建议。
- 对涉及多药合用的患者,应评估三向药物相互作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Letermovir and maribavir have demonstrated efficacy in the prevention and treatment, respectively, of immunosuppressed patients with cytomegalovirus (CMV) infection and disease. These patients often have polypharmacy making them at risk for drug-drug interactions. Both letermovir and maribavir can be perpetrators and victims of drug-drug interactions. Letermovir is a moderate inhibitor of CYP3A, CYP2C8 and OATP1B1/3, and a moderate inducer of CYP2C19. It is a substrate of UGT1A1/3, BCRP, P-gp and OATP1B1/3. Maribavir is a moderate CYP2C9 inhibitor and a substrate of CYP3A. Drug-drug interactions between these anti-CMV agents and a number of therapeutic classes, such as immunosuppressants, antifungal agents, and hemato-oncological agents, can have clinical consequences and deserve dose modification or close monitoring. In a number of examples, three-way drug interactions need to be assessed. The objective of this review is to provide clinicians with guidance for drug-drug interaction management, based on existing data from drug-drug interaction studies, and extrapolation to other relevant co-medications that have not (yet) been studied but that are frequently used in these patient populations.
引用
- Burger DM, Nijboer L, Ghobreyal M, et al. Drug-Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir and Maribavir: Guidance for Clinicians. Clin Pharmacokinet. 2024. PMID: 39509076. doi:10.1007/s40262-024-01437-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。